Pharmanutra S.p.A.
PHN
Rank in Stocks
#9677
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise,... Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
Share Price
$84.51
Last synced: 2026-11-09
Market Cap
$809.17M
Change (1 day)
1.89%
Change (1 year)
44.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pharmanutra S.p.A. (PHN)
Category
Healthcare
EPS for Pharmanutra S.p.A. (PHN)
EPS as of June 2026 TTM: $2.43
According to Pharmanutra S.p.A.'s latest financial reports, its current EPS (TTM) is $2.43. At the end of 2025 the company had an EPS of $2.45, an increase over its 2024 EPS of $1.80.
EPS history for Pharmanutra S.p.A. from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $2.43 | -0.77% |
| 2025 | $2.45 | 36.21% |
| 2024 | $1.80 | 22.44% |
| 2023 | $1.47 | -12.14% |
| 2022 | $1.67 | 3.64% |
| 2021 | $1.61 | -8.56% |
| 2020 | $1.77 | 80.91% |
| 2019 | $0.98 | -3.48% |
| 2018 | $1.01 | 35.95% |
| 2017 | $0.74 | 28.55% |
| 2016 | $0.58 | 44.03% |
| 2015 | $0.40 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 167.43% |
DE
|
|
| $6.08 | 149.99% |
DE
|
|
| $1.55 | -36.22% |
JP
|
|
| $3.66 | 50.55% |
CH
|
|
| $0.45 | -81.49% |
IL
|
Questions about Pharmanutra S.p.A.'s earnings per share (EPS)
What is Pharmanutra S.p.A.'s earnings per share (EPS)?
Pharmanutra S.p.A.'s earnings per share (EPS) over the last twelve months is $2.43, as of Jun 2026.
What was Pharmanutra S.p.A.'s earnings per share (EPS) in 2025?
In 2025, Pharmanutra S.p.A.'s earnings per share (EPS) was $2.45, 36.11% more than in 2024 ($1.80).
How has Pharmanutra S.p.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Pharmanutra S.p.A.'s earnings per share (EPS) went from $1.77 to $2.45, an average growth of 6.72% a year.
How does Pharmanutra S.p.A.'s earnings per share (EPS) compare with similar companies?
Pharmanutra S.p.A.'s earnings per share (EPS) ($2.43) is higher than that of 2 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.